Silexion Plans Reverse Split to Regain Nasdaq Compliance

Silexion Therapeutics ( (SLXN) ) has shared an announcement.

On July 18, 2025, Silexion Therapeutics received a notification from Nasdaq regarding a bid price deficiency, as the company’s shares had closed below $1.00 for 30 consecutive business days. Despite this, Silexion’s shares and warrants will continue trading on Nasdaq, and the company plans a 1-for-15 reverse share split to address the issue. The reverse split, approved by shareholders, is set to take effect on July 28, 2025, with trading on a split-adjusted basis starting July 29, 2025. The company aims to regain compliance with Nasdaq’s requirements by September 19, 2025, but there is no assurance of meeting all listing standards.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics Corp operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is listed on the Nasdaq Capital Market under the symbol ‘SLXN’.

Average Trading Volume: 1,858,171

Technical Sentiment Signal: Sell

Current Market Cap: $7.2M

For an in-depth examination of SLXN stock, go to TipRanks’ Overview page.